PHARMATHENE, INC. | ||||||||
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
Three months ended March 31, | ||||||||
2011 | 2010 | |||||||
Revenue | $ | 6,337,722 | $ | 3,116,553 | ||||
Operating expenses: | ||||||||
Research and development | 5,820,374 | 4,952,393 | ||||||
General and administrative | 4,939,654 | 5,325,422 | ||||||
Depreciation and amortization | 117,629 | 245,258 | ||||||
Total operating expenses | 10,877,657 | 10,523,073 | ||||||
Loss from operations | (4,539,935) | (7,406,520) | ||||||
Other income (expense): | ||||||||
Interest income | 3,154 | 3,483 | ||||||
Interest expense | (15,435) | (948,150) | ||||||
Other income (expense) | (11,906) | 139,422 | ||||||
Change in market value of derivative instruments | 2,488,465 | 267,496 | ||||||
Total other income (expense) | 2,464,278 | (537,749) | ||||||
Net loss | $ | (2,075,657) | $ | (7,944,269) | ||||
Basic and diluted net loss per share | $ | (0.04) | $ | (0.28) | ||||
Weighted average shares used in calculation of basic and diluted net loss per share | 46,276,874 | 28,172,802 | ||||||
